Citius Oncology (CTOR) EBITDA (2023 - 2026)

Citius Oncology's EBITDA history runs 4 years deep, the most recent figure standing at -$28.6 million for Q1 2026.

• In Q1 2026, EBITDA fell 282.98% year-over-year to -$28.6 million; the TTM figure through Mar 2026 stood at -$43.5 million (down 131.95% YoY), while the FY2025 annual figure was -$23.5 million, down 14.34% from the prior year.
• EBITDA was -$28.6 million for Q1 2026 at Citius Oncology, down from -$5.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$147922.0 in Q1 2023 to a low of -$28.6 million in Q1 2026.
• Historically, EBITDA has averaged -$5.6 million across 4 years, with a median of -$4.7 million in 2024.
• Biggest YoY gain for EBITDA was 17.87% in 2025; the steepest drop was 2683.35% in 2025.
• A 4-year view of EBITDA shows it stood at -$4.6 million in 2023, then tumbled by 39.52% to -$6.4 million in 2024, then advanced by 17.87% to -$5.3 million in 2025, then tumbled by 444.78% to -$28.6 million in 2026.
• The last three EBITDA figures came in at -$28.6 million (Q1 2026), -$5.3 million (Q4 2025), and -$4.7 million (Q3 2025), per Business Quant data.